Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

April Armstrong

Showing results (61-70 of 124) with videos related to

Pageof 13
Sort By:
Dermatology and Therapy|July 25, 2023
Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 StudiesLinda Stein Gold, Andreas Pinter, April Armstrong, et al.
The Journal of Dermatological Treatment|January 6, 2025
Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitisAndrew Blauvelt, Leon Kircik, Todd Schlesinger, et al.
The Journal of Dermatological Treatment|August 12, 2017
Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trialApril Armstrong, Luis Puig, Richard Langley, et al.
Dermatology and Therapy|March 14, 2022
Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global SurveyApril Armstrong, Barbra Bohannan, Sicily Mburu, et al.
Journal of Drugs in Dermatology : JDD|March 6, 2023
Evaluating Sentiment, Engagement, and Perception of Biologics Among Patients with Psoriasis and Psoriatic Arthritis on RedditNicole Maynard, Danielle Yee, Camila Carranza, et al.
Dermatology and Therapy|September 24, 2022
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3Andrew Blauvelt, Melinda Gooderham, Neal Bhatia, et al.
Dermatology and Therapy|July 2, 2025
Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council ClassificationBruce Strober, Manish Patel, Mark I Kaldas, et al.
The Journal of Dermatological Treatment|April 3, 2020
Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasisJashin J Wu, Xiaoying Jia, Yang Zhao, et al.
Journal of the American Academy of Dermatology|June 15, 2023
Patient-reported outcomes with sarecycline treatment for acne vulgaris: Pooled analysis of phase 3 clinical studiesJulie C Harper, April Armstrong, Richard G Fried, et al.
Journal of the American Academy of Dermatology|March 6, 2024
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trialsAndrew Blauvelt, April Armstrong, Joseph F Merola, et al.
Pageof 13

Showing results (61-70 of 124) with videos related to

Sort By:
Pageof 13
Dermatology and Therapy|July 25, 2023
Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 StudiesLinda Stein Gold, Andreas Pinter, April Armstrong, et al.
The Journal of Dermatological Treatment|January 6, 2025
Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitisAndrew Blauvelt, Leon Kircik, Todd Schlesinger, et al.
The Journal of Dermatological Treatment|August 12, 2017
Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trialApril Armstrong, Luis Puig, Richard Langley, et al.
Dermatology and Therapy|March 14, 2022
Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global SurveyApril Armstrong, Barbra Bohannan, Sicily Mburu, et al.
Journal of Drugs in Dermatology : JDD|March 6, 2023
Evaluating Sentiment, Engagement, and Perception of Biologics Among Patients with Psoriasis and Psoriatic Arthritis on RedditNicole Maynard, Danielle Yee, Camila Carranza, et al.
Dermatology and Therapy|September 24, 2022
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3Andrew Blauvelt, Melinda Gooderham, Neal Bhatia, et al.
Dermatology and Therapy|July 2, 2025
Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council ClassificationBruce Strober, Manish Patel, Mark I Kaldas, et al.
The Journal of Dermatological Treatment|April 3, 2020
Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasisJashin J Wu, Xiaoying Jia, Yang Zhao, et al.
Journal of the American Academy of Dermatology|June 15, 2023
Patient-reported outcomes with sarecycline treatment for acne vulgaris: Pooled analysis of phase 3 clinical studiesJulie C Harper, April Armstrong, Richard G Fried, et al.
Journal of the American Academy of Dermatology|March 6, 2024
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trialsAndrew Blauvelt, April Armstrong, Joseph F Merola, et al.
Pageof 13